Biotech Values

[DewDiligence]

Humira goes off-patent in the US in late 2016; Orencia goes off in 2019, but the patent protection on Orencia may be subject to a workaround; Erbitux is already off-patent in the US. IVIG has various “use” patents, but the composition of matter is in the public domain.

The table in #msg-70191760 (which is referenced by the MNTA ReadMeFirst), is a good starting point for questions on patent expirations of big-selling biologics. However, this table is not the final word because biologics do not have a centralized database similar to the FDA Orange Book. Thus, it requires an inordinate amount of DD to ferret out all of the patents and patent applications that could conceivably be relevant to a given US FoB application.